N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide
N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide Basic information
- Product Name:
- N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide
- Synonyms:
-
- N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide
- SY-1365
- SY-1365;SY 1365;SY1365
- 2-Pyridinecarboxamide, N-[(1S,3R)-3-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-methylcyclohexyl]-5-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-
- N-[(1S,3R)-3-[[5-Chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-methylcyclohexyl]-5-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-2-pyridinecarboxamide
- Mevociclib
- Mevociclib，SY-1365
- Inhibitor,triple negative breast cancer,TNBC,Mevociclib,Cyclin dependent kinase,SY1365,tumors,cancers,cell,inhibit,solid,CDK,small,SY 1365,CDK7/CycH/MAT1,lung
- CAS:
- 1816989-16-8
- MF:
- C31H35ClN8O2
- MW:
- 587.11
- Product Categories:
-
- SY-1365
- Mol File:
- 1816989-16-8.mol
More
Less
N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide Chemical Properties
- Density
- 1.34±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO: 125 mg/mL (212.90 mM)
- form
- Solid
- pka
- 12.04±0.70(Predicted)
- color
- White to off-white
More
Less
N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamide Usage And Synthesis
Uses
N-[(1S,3R)-3-[[5-Chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]-1-methylcyclohexyl]-5-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-2-pyridinecarboxamide is a CDK7 inhibitor and is used for anticancer treatments.
in vivo
Mevociclib (20mg/kg; i.v.; biw; for 35 days) inhibits tumor growth in TNBC in vivo models[2].
?
Mevociclib induces unique transcriptional signature[2].
| Animal Model: | Mice, HCC70 xenograft model[2] |
| Dosage: | 20 mg/kg |
| Administration: | Intravenous injection, twice weekly, for 35 days |
| Result: | Inhibited tumor volume in vivo. |
IC 50
CDK7
N-((1S,3R)-3-(5-chloro-4-(1H-indol-3-yl)pyrimidin-2-ylamino)-1-methylcyclohexyl)-5-((E)-4-(dimethylamino)but-2-enamido)picolinamideSupplier
ShangHai Caerulum Pharma Discovery Co., Ltd.
- Tel
- 18149758185
- sales-cpd@caerulumpharma.com
Shanghai YuanQi Biotechnology Co., Ltd.
- Tel
- +86-2332782371 +86-18120098618
- sales@adobechem.com
Shanghai SuperLan Chemcial Technique Centre
- Tel
- 0-2022843681 15618226720
- chaolaichem@foxmail.com
Amadis Chemical Company Limited
- Tel
- 571-89925085
- sales@amadischem.com
TargetMol Chemicals Inc.
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com